Skip to main content

eFFECTOR Therapeutics, Inc.

EFTRDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001828522

eFFECTOR Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Jun 13, 2024; 1 institution reported holding it in 13F filings for Q4 2025, worth $0 in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
1
Q4 2025, 0 vs. previous quarter
13F value
$0
Reported value at the end of Q4 2025
Superinvestors holding
0
At the end of Q4 2025

Superinvestors holding EFTR, Q4 2025

Go to the superinvestors tab

No superinvestor reported holding EFTR at the end of Q4 2025.

Latest insider trades

Open-market purchases and sales by eFFECTOR Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 29, 2023 (view filing)5:07 PM ETNov 272 daysGeorge Simeon and 5 others10% OwnerSSale−609.2K$0.6065−$369.5K−25.1%1.82M after2 lots
Oct 6, 2022 (view filing)Oct 42 daysEhrlich Christopher BDirectorPPurchase+346$0.57+$197.22+1.0%35.2K after
Sep 27, 2022 (view filing)Sep 261 dayEhrlich Christopher BDirectorPPurchase+18.9K$0.55+$10.4K+117.9%34.9K after
Aug 3, 2022 (view filing)5:58 PM ETAug 1-32 daysRoot Jonathan D and 4 others10% OwnerSSale−114.3K$0.7981−$91.2K−47.3%127.6K after6 lots
Jul 29, 2022 (view filing)8:54 PM ETJul 281 dayRoot Jonathan D and 4 others10% OwnerSSale−32.5K$0.892−$29.0K−19.9%131.0K after2 lots
Jul 27, 2022 (view filing)6:20 PM ETJul 25-272 daysRoot Jonathan D and 4 others10% OwnerSSale−48.7K$0.8945−$43.6K−27.0%132.0K after6 lots
Jul 22, 2022 (view filing)6:03 PM ETJul 20-222 daysRoot Jonathan D and 4 others10% OwnerSSale−20.3K$0.9609−$19.5K−13.2%133.5K after6 lots
Jul 19, 2022 (view filing)4:54 PM ETJul 15-194 daysRoot Jonathan D and 4 others10% OwnerSSale−69.6K$1.10−$76.3K−34.2%134.1K after6 lots
Jun 27, 2022 (view filing)Jun 234 daysGallagher Brian M. Jr.DirectorPPurchase+30.0K$1.59+$47.7KNew position30.0K after
Jun 9, 2022 (view filing)Jun 72 daysWorland Stephen TPresident and Chief ExecutivePPurchase+20.0K$1.37+$27.4K+10.3%215.0K after

Top 10 13F holders, Q4 2025

The largest institutional positions in eFFECTOR Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.

See all 1 holders
Institutions holding EFTR in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Proathlete Wealth Management LLC12$00.00%00.0%Unchanged